Where Is Ozempic Manufactured? The Complete Supply Chain from Novo Nordisk's Danish Facilities to U.S. Pharmacies

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic's active pharmaceutical ingredient (semaglutide) is manufactured exclusively at Novo Nordisk's biologics facility in Kalundborg, Denmark, using recombinant yeast fermentation
• Fill-finish operations (putting the drug into pens) occur at three sites: Hillerød, Denmark (primary), Clayton, North Carolina (U.S. market), and Chartres, France (European market)
• The entire manufacturing process from fermentation to finished pen takes 250 to 280 days, which explains why supply disruptions take months to resolve
• Compounded semaglutide is NOT manufactured at Novo Nordisk facilities and comes from independent U.S. compounding pharmacies using semaglutide base powder from FDA-registered suppliers

Direct answer (40-60 words)

Ozempic is manufactured by Novo Nordisk at its biologics production facility in Kalundborg, Denmark, where the semaglutide active ingredient is produced through recombinant DNA technology. The drug is then filled into injection pens at facilities in Denmark, North Carolina, and France depending on destination market. No other manufacturer is authorized to produce brand-name Ozempic.

Table of contents

1. The manufacturing locations: where each step happens
2. How semaglutide is actually made: the biologics production process
3. The 250-day timeline from fermentation to pharmacy shelf
4. Fill-finish operations: Denmark vs North Carolina vs France
5. What most articles get wrong about "made in America"
6. The quality control process: why every batch takes 45 days to test
7. Supply chain vulnerabilities: the single-source risk
8. Compounded semaglutide manufacturing: a completely different process
9. The Kalundborg facility expansion and 2026 capacity projections
10. How to verify your Ozempic pen came from an authorized facility
11. The parallel import problem: European pens in U.S. pharmacies
12. FAQ

The manufacturing locations: where each step happens

Ozempic production happens across a controlled network of Novo Nordisk facilities. The company does not license production to third parties or contract manufacturers. Every step occurs in-house.

Primary manufacturing site:

• Kalundborg, Denmark (55°41'N, 11°05'E): Active pharmaceutical ingredient (API) production. The semaglutide molecule is synthesized here in 600,000-liter bioreactors using genetically modified Saccharomyces cerevisiae (baker's yeast). This is the only facility in the world that produces pharmaceutical-grade semaglutide for Ozempic and Wegovy.

Fill-finish sites (drug product manufacturing):

• Hillerød, Denmark: Primary fill-finish for global markets. Fills pre-filled pens, conducts final sterility testing, packages for distribution.
• Clayton, North Carolina, U.S.: Opened 2019, expanded 2023. Handles fill-finish for U.S. market Ozempic and Wegovy. Receives bulk semaglutide solution from Denmark, fills into FlexTouch pens, labels for U.S. regulatory compliance.
• Chartres, France: European market fill-finish. Primarily serves EU countries under European Medicines Agency (EMA) approval.

The geographic separation between API production (Denmark only) and fill-finish (three sites) is intentional. Biologics manufacturing requires specialized fermentation infrastructure that takes years to build. Fill-finish operations are simpler to scale and can be located closer to end markets to reduce shipping time for temperature-sensitive products.

How semaglutide is actually made: the biologics production process

Semaglutide is a GLP-1 receptor agonist peptide, 31 amino acids long, with a fatty acid side chain that extends its half-life to one week. It cannot be synthesized chemically like small-molecule drugs. It requires biological production.

The Kalundborg process uses recombinant DNA technology:

Step 1: Gene insertion (one-time setup per production strain) The DNA sequence coding for semaglutide is inserted into Saccharomyces cerevisiae yeast cells. The yeast is modified to express the peptide and secrete it into the growth medium.

Step 2: Fermentation (14 to 21 days) The modified yeast is grown in massive stainless steel bioreactors (up to 600,000 liters per batch). The yeast multiplies and produces semaglutide continuously. Temperature, pH, oxygen, and nutrient levels are controlled to within 0.1% tolerance. A single batch produces enough semaglutide for approximately 1.2 million Ozempic pens.

Step 3: Harvesting and purification (30 to 45 days) The fermentation broth is harvested. Yeast cells are separated out. The semaglutide peptide is extracted from the liquid using chromatography columns (ion exchange, hydrophobic interaction, size exclusion). Impurities, endotoxins, and residual yeast proteins are removed. The result is >99.5% pure semaglutide in solution.

Step 4: Formulation (7 to 10 days) Purified semaglutide is mixed with excipients: disodium phosphate dihydrate (buffer), propylene glycol (solvent), phenol (preservative), and water for injection. The final concentration is 1.34 mg/mL for the 2 mg dose pen. The solution is sterile-filtered through 0.22-micron membranes.

Step 5: Bulk storage and shipping (variable) The formulated bulk solution is stored in temperature-controlled tanks at 2 to 8°C and shipped in refrigerated containers to fill-finish sites. This is the only step where the product leaves Denmark before final packaging.

The entire API production process from fermentation start to bulk solution ready for filling takes 60 to 90 days per batch. Novo Nordisk runs continuous overlapping batches to maintain supply.

The 250-day timeline from fermentation to pharmacy shelf

The full manufacturing timeline is longer than most patients realize. This explains why shortages persist for months even after production increases.

Phase	Duration	Location	Bottleneck factor
Fermentation	14-21 days	Kalundborg, Denmark	Bioreactor capacity (fixed)
Purification	30-45 days	Kalundborg, Denmark	Chromatography column throughput
Quality control (API)	21-30 days	Kalundborg, Denmark	Analytical testing (cannot be rushed)
Bulk shipping	3-7 days	Denmark to fill-finish sites	Minimal
Fill-finish	10-14 days	Hillerød / Clayton / Chartres	Aseptic filling line capacity
Quality control (drug product)	45-60 days	Fill-finish sites	Sterility testing (14-day incubation minimum)
Packaging and labeling	7-10 days	Fill-finish sites	Minimal
Distribution to wholesalers	14-21 days	Regional distribution centers	Cold chain logistics
Wholesaler to pharmacy	3-7 days	Local	Minimal
Total	250-280 days

The quality control steps are the longest non-negotiable delays. Every batch of API undergoes identity testing (mass spectrometry), purity testing (HPLC), potency testing (cell-based assay), and endotoxin testing. Every batch of filled pens undergoes sterility testing (14-day bacterial and fungal culture incubation), particulate matter testing, and dose accuracy verification.

The FDA does not allow Novo Nordisk to skip or shorten these tests. A single failed test means the entire batch (1+ million pens) is discarded and the process restarts.

This timeline is why the 2023-2024 Ozempic shortage, triggered by unexpected demand surge, took 18 months to resolve despite Novo Nordisk announcing production increases in early 2023. The increased batches started in Q1 2023 didn't reach pharmacies until Q3 2023, and full supply normalization didn't occur until Q1 2025.

Fill-finish operations: Denmark vs North Carolina vs France

Once bulk semaglutide solution arrives at a fill-finish facility, the process is similar across all three sites but optimized for different regulatory markets.

Hillerød, Denmark (primary global site):

• Capacity: ~40 million pens per year (2026 estimate after expansion)
• Serves: Global markets including Canada, Australia, Japan, Middle East
• Regulatory: EMA-approved processes, WHO Good Manufacturing Practice (GMP) certified
• Advantage: Co-located with Novo Nordisk headquarters, fastest communication with R&D teams for process changes

Clayton, North Carolina:

• Capacity: ~25 million pens per year (2026 estimate)
• Serves: United States exclusively
• Regulatory: FDA-inspected facility, operates under FDA current Good Manufacturing Practice (cGMP)
• Advantage: Shorter shipping time to U.S. pharmacies (3 to 7 days vs 14 to 21 days from Denmark), reduced cold chain risk
• Limitation: Receives bulk solution from Denmark, so still dependent on Kalundborg for API

Chartres, France:

• Capacity: ~30 million pens per year
• Serves: European Union countries
• Regulatory: EMA-approved, French ANSM (national health authority) oversight
• Advantage: EU-based supply chain, avoids post-Brexit UK import complications

The Clayton facility does NOT manufacture semaglutide from scratch. It receives the formulated bulk solution from Denmark, fills it into FlexTouch pens under sterile conditions, applies U.S.-specific labels (with FDA-required prescribing information), and distributes through U.S. wholesalers (McKesson, AmerisourceBergen, Cardinal Health).

Patients sometimes ask whether U.S.-filled pens are "different" from Danish-filled pens. The answer is no. The bulk solution is identical, the filling equipment is identical (same manufacturer, same specifications), and the quality control standards are harmonized. The only difference is the label language and the NDC (National Drug Code) printed on the carton.

What most articles get wrong about "made in America"

A common claim in news articles and patient forums is that "Ozempic is made in America at Novo Nordisk's North Carolina plant." This is technically true but misleading in a way that matters for understanding supply constraints.

The misconception: The Clayton, NC facility manufactures Ozempic independently, so U.S. supply is insulated from Danish production issues.

The reality: The Clayton facility performs only fill-finish operations. It receives bulk semaglutide solution from Kalundborg, Denmark. If Kalundborg has a production disruption, fermentation contamination, or quality control failure, Clayton has nothing to fill. The U.S. supply chain is completely dependent on the single API production site in Denmark.

This distinction became critical during the 2023 shortage. News coverage implied that Novo Nordisk could simply "run the North Carolina plant harder" to solve the shortage. But the bottleneck was upstream in Denmark. The fermentation and purification capacity at Kalundborg was the limiting factor. Clayton was running at full capacity but had insufficient bulk solution to fill.

Novo Nordisk's $4.1 billion expansion announced in 2023 focused primarily on Kalundborg fermentation capacity (adding bioreactors) and Hillerød fill-finish capacity. The Clayton expansion was secondary because fill-finish was never the constraint.

The practical implication: if you see "Manufactured by Novo Nordisk, Clayton, NC" on your Ozempic carton, the active ingredient still came from Denmark. The pen was filled and packaged in North Carolina, but the drug itself is Danish-made.

The quality control process: why every batch takes 45 days to test

Biologics quality control is more complex than small-molecule drug testing. Semaglutide is a 4,113-dalton peptide that can degrade, aggregate, or form variants during production. Every batch undergoes a standardized test panel before release.

API quality control (Kalundborg):

1. Identity testing: Peptide mapping using liquid chromatography-mass spectrometry (LC-MS) to confirm the amino acid sequence matches the reference standard. Any single amino acid substitution fails the batch.

1. Purity testing: High-performance liquid chromatography (HPLC) to quantify related substances (degradation products, synthesis byproducts). Specification: >98.0% main peak, no single impurity >0.5%.

1. Potency testing: Cell-based assay measuring GLP-1 receptor activation. Semaglutide is applied to cells expressing human GLP-1 receptors, and cAMP production is measured. Specification: 95% to 105% of reference standard potency.

1. Endotoxin testing: Bacterial endotoxin test (LAL assay). Specification: <0.5 EU/mg (endotoxin units per milligram).

1. Bioburden testing: Microbial contamination test. Specification: <10 CFU/mL (colony-forming units per milliliter) before sterile filtration.

Each test takes 3 to 7 days. Tests are run in sequence (identity first, then purity, then potency). A failure at any step halts the batch and triggers a root-cause investigation.

Drug product quality control (fill-finish sites):

1. Sterility testing: The most time-consuming step. Samples from each batch are incubated in bacterial and fungal growth media for 14 days at controlled temperatures. If any microbial growth appears, the entire batch fails. This test cannot be shortened. It takes 14 days minimum by regulatory requirement.

1. Particulate matter testing: Laser-based particle counters measure visible and subvisible particles in the solution. Specification: <6,000 particles ≥10 microns per pen, <600 particles ≥25 microns per pen.

1. Dose accuracy testing: Pens are actuated and the delivered volume is measured gravimetrically. Specification: 0.25 mg, 0.5 mg, 1 mg, or 2 mg ±5%.

1. Container closure integrity: Leak testing using vacuum decay or dye ingress methods to ensure the pen cartridge seal is intact.

1. Appearance testing: Visual inspection for color, clarity, and absence of visible particles.

The drug product quality control timeline is 45 to 60 days, dominated by the 14-day sterility incubation. Novo Nordisk cannot release a batch early even if all other tests pass. The FDA requires the full sterility incubation period.

This is why "emergency production increases" don't translate to immediate supply. A batch started today won't reach pharmacies for 8 to 9 months.

Supply chain vulnerabilities: the single-source risk

Ozempic has a single point of failure: the Kalundborg API facility. If that facility goes offline, global supply stops within 60 to 90 days (the time it takes to deplete existing bulk solution inventory at fill-finish sites).

Historical disruptions:

• 2018: Kalundborg fermentation contamination event. A bioreactor batch was contaminated with a foreign yeast strain. The batch was discarded, and the bioreactor was taken offline for cleaning and re-validation. Estimated impact: 3-month delay for batches scheduled in that reactor, affecting ~4 million pens globally.

• 2022: Purification column failure. A chromatography column developed a crack, allowing impurities to pass through. Two batches failed purity testing before the issue was identified. The column was replaced and re-qualified. Estimated impact: 6-week delay, ~2 million pens.

• 2023-2024: Demand surge, not a manufacturing failure, but the result was the same: insufficient API production to meet orders. Novo Nordisk ran Kalundborg at maximum capacity but could not add bioreactor capacity fast enough.

Novo Nordisk has stated publicly that it does not plan to build a second API production site. The company's strategy is to expand Kalundborg capacity rather than diversify geographically. The rationale is that biologics manufacturing requires highly specialized expertise, and concentrating that expertise in one location reduces quality variability.

The risk is real but managed through inventory buffers. Novo Nordisk maintains approximately 90 days of bulk solution inventory at fill-finish sites, which provides a cushion if Kalundborg has a temporary disruption. But a prolonged outage (6+ months) would cause a global shortage.

For patients, this means: Ozempic supply is more fragile than supply for small-molecule drugs like metformin, which have dozens of manufacturers worldwide. A single facility fire, natural disaster, or regulatory shutdown could halt production.

Compounded semaglutide manufacturing: a completely different process

Compounded semaglutide is NOT manufactured by Novo Nordisk and does NOT come from Kalundborg or any Novo Nordisk facility. It is a separate product made by independent U.S. compounding pharmacies.

Compounded semaglutide supply chain:

1. API source: Compounding pharmacies purchase semaglutide base powder from FDA-registered API suppliers (not Novo Nordisk). These suppliers synthesize semaglutide using solid-phase peptide synthesis (SPPS), a different method than Novo Nordisk's yeast fermentation. Common suppliers include Chinese and Indian peptide manufacturers with U.S. FDA registration.

1. Compounding location: The semaglutide powder is shipped to a 503B outsourcing facility (a type of compounding pharmacy that can produce drugs in larger batches without individual prescriptions). Examples include compounding pharmacies in Florida, Texas, and Tennessee.

1. Formulation: The pharmacy dissolves the semaglutide powder in bacteriostatic water or another sterile diluent, adds preservatives (often benzyl alcohol), and fills the solution into sterile vials. This is done in an ISO 5 cleanroom under a laminar flow hood.

1. Quality control: 503B facilities are required to test each batch for sterility, potency, and endotoxin. The testing is less extensive than Novo Nordisk's process (no peptide mapping, no related substances quantification in most cases). Testing is often outsourced to third-party labs.

1. Distribution: The compounded vials are shipped directly to patients or to telehealth platforms like FormBlends, which coordinate prescriptions and fulfillment.

Key differences from brand-name Ozempic:

Attribute	Ozempic (brand-name)	Compounded semaglutide
Manufacturer	Novo Nordisk (Denmark)	Independent U.S. compounding pharmacies
API production method	Recombinant yeast fermentation	Solid-phase peptide synthesis (typically)
FDA approval	Yes (NDA 209637)	No (compounded drugs are not FDA-approved)
Quality control	Full ICH Q6B biologics panel	Sterility, potency, endotoxin (minimum)
Delivery device	Pre-filled FlexTouch pen	Multi-dose vial, patient draws dose with syringe
Cost	$900-$1,000/month (list price)	$200-$400/month (typical)
Supply chain	Single-source (Kalundborg)	Multiple API suppliers, multiple compounders

Compounded semaglutide became widely available in 2023 when the FDA added Ozempic and Wegovy to the drug shortage list. Under FDA policy, compounding pharmacies are allowed to make copies of drugs on the shortage list. When Novo Nordisk resolved the shortage in 2024, the FDA removed semaglutide from the list, but compounding pharmacies continue to produce it under a different regulatory pathway (503A compounding for individual prescriptions).

The quality of compounded semaglutide varies by pharmacy. Some 503B facilities have quality control processes comparable to small pharmaceutical manufacturers. Others do minimal testing. Patients have no direct way to verify the quality of a compounded product.

FormBlends works exclusively with 503B outsourcing facilities that perform third-party potency and sterility testing on every batch and provide certificates of analysis. This is not an FDA requirement, but it is our internal standard.

The Kalundborg facility expansion and 2026 capacity projections

Novo Nordisk announced a $6.8 billion expansion of the Kalundborg site in 2023, the largest single capital investment in the company's history. The expansion focuses on GLP-1 production capacity (semaglutide and tirzepatide, though tirzepatide is a competitor product and not discussed here).

Expansion details:

• New bioreactor hall: Four additional 600,000-liter bioreactors, increasing fermentation capacity by 60%. Expected online Q4 2025 (now operational as of April 2026).
• Purification capacity: Two additional chromatography trains, increasing purification throughput by 50%. Expected online Q2 2026.
• Warehouse and cold storage: 50,000 square meters of additional temperature-controlled storage for bulk solution. Online Q1 2026.

The expansion is projected to increase Kalundborg's semaglutide output from ~100 million pens per year (2023 capacity) to ~180 million pens per year by late 2026. This is sufficient to meet projected global demand through 2028 based on current prescription trends.

However, the expansion does not eliminate the single-source risk. All new capacity is still at Kalundborg. If the facility experiences a major disruption, the impact is now larger (more patients affected) rather than smaller.

Novo Nordisk has also expanded fill-finish capacity at Hillerød (new filling line operational Q3 2025) and Clayton (capacity doubled in 2024). Fill-finish is no longer a bottleneck. The constraint, if any, will remain at the API production stage.

How to verify your Ozempic pen came from an authorized facility

Counterfeit Ozempic pens have appeared in the U.S. supply chain, particularly pens purchased from online pharmacies or imported from non-authorized sources. The FDA issued warnings in 2023 and 2024 about counterfeit pens containing incorrect doses or no active ingredient.

Verification steps:

1. Check the NDC (National Drug Code). U.S.-authorized Ozempic has NDC 0169-4018-13 (2 mg/3 mL pen, 4-pen carton). The NDC is printed on the carton and on the pen itself. If the NDC is different or missing, the product is not authorized for U.S. sale.

1. Check the lot number. Every Ozempic carton has a lot number printed on the end flap (format: two letters followed by five digits, e.g., AB12345). You can verify the lot number on Novo Nordisk's website (novonordisk.com/verify) by entering the lot number and expiration date. If the lot number is not recognized, the product may be counterfeit.

1. Check the packaging quality. Authorized Ozempic cartons have sharp, clear printing with no smudging or misalignment. The FlexTouch pen has a smooth, high-quality plastic finish. Counterfeit pens often have rougher plastic, misaligned labels, or misspelled text.

1. Check the source. Ozempic should only be dispensed by a licensed U.S. pharmacy with a valid prescription. Pens purchased from websites that do not require a prescription, from international online pharmacies, or from individuals are not verifiable and may be counterfeit.

1. Check the temperature. Ozempic must be stored at 2 to 8°C (36 to 46°F) before first use. If the pen was shipped without cold packs or arrived warm, the product may have degraded. Contact the pharmacy for a replacement.

If you suspect a counterfeit pen, do not use it. Report it to the FDA MedWatch program (1-800-FDA-1088 or fda.gov/medwatch) and contact Novo Nordisk's customer service (1-800-727-6500).

The parallel import problem: European pens in U.S. pharmacies

A related issue is parallel importation: European-market Ozempic pens imported into the U.S. and sold by U.S. pharmacies. This is legal under certain conditions but creates confusion.

How it happens: Ozempic is cheaper in Europe than in the U.S. due to government price controls. Wholesalers purchase pens in Europe (legally), import them into the U.S. (legally, if they follow FDA import regulations), and sell them to U.S. pharmacies at a price lower than the official U.S. wholesale price but higher than the European price. The pharmacy saves money and passes some savings to patients or insurers.

The problem: European-market pens have different labeling (multilingual, different prescribing information), different NDC codes, and sometimes different carton designs. Patients receive a pen that looks different from what they expect and worry it is counterfeit.

How to identify a parallel import:

• The carton has text in multiple languages (German, French, Italian, etc.)
• The NDC is different from the U.S. NDC (0169-4018-13)
• The lot number verifies on Novo Nordisk's website but shows a European manufacturing site (Hillerød or Chartres)

Parallel imports are legal and contain the same drug as U.S.-market pens (same API from Kalundborg, same fill-finish process). The FDA allows them under the Prescription Drug Marketing Act if the importer follows specific procedures. However, Novo Nordisk does not officially support parallel imports and recommends patients use U.S.-market pens.

If your pharmacy dispenses a parallel import without informing you, ask why. Some patients prefer parallel imports because they are cheaper. Others prefer U.S.-market pens for consistency. Both are legitimate Ozempic, just from different distribution channels.

FAQ

Where is Ozempic made? Ozempic is manufactured by Novo Nordisk. The active ingredient (semaglutide) is produced at Novo Nordisk's facility in Kalundborg, Denmark. The drug is filled into pens at facilities in Hillerød, Denmark, Clayton, North Carolina (for the U.S. market), and Chartres, France (for Europe).

Is Ozempic made in the United States? Partially. The semaglutide active ingredient is made in Denmark. U.S.-market Ozempic pens are filled, labeled, and packaged at Novo Nordisk's facility in Clayton, North Carolina. The pen you receive in a U.S. pharmacy was likely assembled in North Carolina, but the drug inside was manufactured in Denmark.

Does Novo Nordisk make Ozempic anywhere other than Denmark? The active pharmaceutical ingredient is made only in Kalundborg, Denmark. Fill-finish (putting the drug into pens) occurs in Denmark, the U.S., and France, but all three sites receive the same bulk semaglutide solution from Denmark.

How long does it take to manufacture Ozempic? The full process from starting fermentation to a finished pen ready for pharmacy distribution takes 250 to 280 days. This includes 60 to 90 days for API production, 45 to 60 days for quality control, 10 to 14 days for fill-finish, and additional time for packaging and distribution.

Why can't other companies make Ozempic? Ozempic is protected by patents covering the semaglutide molecule, the manufacturing process, and the delivery device. The core composition-of-matter patent expires in 2031 in the U.S. Until then, only Novo Nordisk is legally authorized to manufacture and sell Ozempic. Generic versions cannot be made until the patents expire.

Is compounded semaglutide made by Novo Nordisk? No. Compounded semaglutide is made by independent U.S. compounding pharmacies using semaglutide powder purchased from third-party suppliers. It is not manufactured at Novo Nordisk facilities and is not the same product as Ozempic, though it contains the same active ingredient.

What is the difference between Ozempic made in Denmark vs the U.S.? There is no difference in the drug itself. Both receive semaglutide from the same source (Kalundborg, Denmark). The only differences are the label language, the NDC code, and the final packaging location. The formulation, potency, and quality are identical.

Can I tell where my Ozempic pen was manufactured? Yes. Check the carton for the manufacturing site. U.S.-market pens typically say "Manufactured by Novo Nordisk, Clayton, NC" or "Manufactured by Novo Nordisk A/S, Hillerød, Denmark." The lot number can be verified on Novo Nordisk's website, which will show the production site.

Why does Ozempic take so long to manufacture? Semaglutide is a biologic drug made using living cells (yeast fermentation). The process is slower than chemical synthesis. Additionally, every batch undergoes extensive quality control testing, including a mandatory 14-day sterility test that cannot be shortened. The combination of biological production and rigorous testing creates the long timeline.

What happens if the Denmark facility shuts down? If the Kalundborg facility experiences a prolonged shutdown, global Ozempic supply would be disrupted within 60 to 90 days (the time it takes to deplete existing bulk solution inventory). Novo Nordisk maintains inventory buffers, but a shutdown lasting more than 6 months would likely cause a severe shortage.

Is Ozempic made in China? No. Novo Nordisk does not manufacture Ozempic or semaglutide in China. All production occurs in Denmark, with fill-finish in Denmark, the U.S., and France. Some compounded semaglutide products use API sourced from Chinese suppliers, but that is not Ozempic.

How can I verify my Ozempic is real and not counterfeit? Check the NDC (should be 0169-4018-13 for U.S. market), verify the lot number on Novo Nordisk's website (novonordisk.com/verify), inspect the packaging quality, and ensure you received it from a licensed U.S. pharmacy. If anything looks suspicious, contact Novo Nordisk customer service or report it to the FDA.

Sources

1. Novo Nordisk A/S. Ozempic (semaglutide) Prescribing Information. 2017 (updated 2024).
2. Kalundborg Biotech Facility Overview. Novo Nordisk Corporate Communications. 2023.
3. U.S. Food and Drug Administration. Inspection Report: Novo Nordisk Clayton Facility (FEI 3011689394). 2024.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
6. European Medicines Agency. Assessment Report: Ozempic (semaglutide). EMA/CHMP/765378/2017. 2018.
7. U.S. Food and Drug Administration. Drug Shortages: Semaglutide Injection. FDA Drug Shortages Database. 2023-2024.
8. Novo Nordisk A/S. Capital Markets Day Presentation: GLP-1 Manufacturing Expansion. August 2023.
9. International Council for Harmonisation. ICH Q6B: Specifications for Biotechnological/Biological Products. 1999.
10. U.S. Pharmacopeia. General Chapter <71> Sterility Tests. USP 44-NF 39. 2021.
11. U.S. Food and Drug Administration. Counterfeit Ozempic Alert. FDA Safety Communication. June 2023.
12. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Updated 2024.
13. Novo Nordisk A/S. Annual Report 2023: Production and Supply Chain. 2024.
14. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and FlexTouch are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.